Medroxyprogesterone acetate dispersible tablets

Animal experiments show that this product has a certain inhibitory effect on transplanted tumors, such as breast cancer tumors. Its anti-tumor effect is related to its progesterone activity. Long-term or overdose use may produce symptoms similar to those of hormone drugs.

The main ingredients of this product and its chemical name are: The main ingredient of this product is medroxyprogesterone acetate. Its chemical name is: 6alpha;-methyl-17alpha;-hydroxypregnane-4-ene-3,20-dione acetate. Its molecular formula: C24H34O4, molecular weight: 386.53.

This product is white dispersible tablets.

Used for palliative or adjuvant treatment of inoperable, recurrent or metastatic hormone-dependent tumors, such as endometrial cancer, renal cancer, breast cancer, etc.

This product must be taken under doctor's advice. Endometrial cancer and kidney cancer: 0.2-0.4g per day; breast cancer: 0.4-0.8g per day, or even up to 1g per day. Sex hormone therapy requires at least 8 to 10 weeks of treatment to respond. Palliative treatment of cachexia and pain in patients with various cancers: 0.5-1g per day. Bone marrow protection during chemotherapy for various cancers: 0.5-1g per day (from one week before chemotherapy to one week after a course of treatment).

1. Similar to other progesterone drugs, breast pain, galactorrhea, amenorrhea, cervical erosion or changes in cervical secretion, and gynecomastia may occur. 2. Mental aspects: nervousness, insomnia, lethargy, fatigue, dizziness. 3. Skin and mucous membranes: Allergic reactions including itching, hives, angioedema to systemic rash and defenseless reactions have been reported. In a few cases, there are reports of acne, baldness or hirsutism. 4. Gastrointestinal tract: Nausea and indigestion, especially at higher doses. 5. It may also produce similar adrenal cortisol reactions and hypercalcemia reactions, and there are occasional reports of obstructive jaundice.

It is contraindicated for patients who are allergic to medroxyprogesterone acetate and any other ingredients of this product, various thromboembolic diseases (thrombophlebitis, pulmonary embolism, etc.), severe liver damage, hypercalcemia due to tumor bone metastasis, menorrhagia, and pregnant or lactating women.

Precautions during pregnancy and lactation: Progesterone drugs have potential harm to the fetus, so this product is not recommended during pregnancy. Lactating women should stop breastfeeding during medication. Women of childbearing age who are about to take this product should avoid pregnancy. It is contraindicated for pregnant or lactating women.

Not yet clear.

Keep in a light-proof and airtight container.

0.1 g

24 months